Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Bitcoin

Strategy Shares Trade at Unprecedented Discount to Bitcoin Holdings

Andreas Sommer by Andreas Sommer
November 16, 2025
in Bitcoin, Crypto Stocks, Earnings, Trading & Momentum
0
Strategy Stock
0
SHARES
22
VIEWS
Share on FacebookShare on Twitter

Strategy Inc, once celebrated as a pioneering force in corporate Bitcoin adoption, is currently navigating its most severe market test. For the first time since early 2024, the company’s shares are trading below their calculated Bitcoin value, despite announcing record-breaking third-quarter profits. This divergence raises critical questions about investor confidence in the firm’s long-term strategy.

Investor Skepticism Overshadows Record Earnings

The Q3 2025 financial results presented what should have been a triumphant narrative: $2.8 billion in net profit and $3.9 billion in operating income—a dramatic reversal from the $432 million loss recorded during the same period last year. The company’s Bitcoin treasury expanded to 640,808 BTC, while annual projections remained optimistic, forecasting $24 billion in net profit and $80 earnings per share, predicated on Bitcoin reaching $150,000 by year-end.

Market reality tells a different story. Despite Bitcoin’s relative stability, Strategy shares have declined approximately 40% over six months. The crucial metric—the Market-to-Net-Asset-Value ratio—has fallen below 1.0, indicating investors now value the stock at a discount rather than the premium it historically commanded. This represents a significant shift from one year ago when the premium stood at 2.7.

Aggressive Acquisition Strategy Faces Mounting Criticism

The company continues its Bitcoin accumulation unabated, demonstrating no deviation from its established path. In mid-November, Strategy deployed another $50 million to purchase 487 Bitcoin at an average price of $102,557. Throughout 2025, the firm has raised $20 billion through capital markets, primarily via stock offerings and convertible bonds.

Executive Chairman Michael Saylor publicly maintains that Bitcoin will ultimately “outperform” both gold and the S&P 500 over the long term. However, this persistent acquisition comes with consequences—each purchase temporarily diminishes per-share value through dilution. Investors increasingly question whether Strategy provides sufficient added value compared to direct Bitcoin ownership.

Should investors sell immediately? Or is it worth buying Strategy?

Compounding these concerns, Executive Vice President Shao Wei-Ming sold shares worth $2.58 million during this critical period. Although executed under a pre-arranged trading plan, the timing sends an unfortunate signal to the market.

The Bitcoin Treasury Model Under Pressure

Strategy’s transformation from software provider to the world’s first “Bitcoin Treasury Company” faces its most significant challenge. The viability of this business model depends entirely on market acceptance of its underlying financial logic.

In a move signaling growing pressure to retain investor interest, the company recently increased the dividend on its STRC preferred shares to 10.5%. The coming weeks will prove decisive for Strategy’s valuation. If Bitcoin maintains its recent recovery, confidence could return. However, should the cryptocurrency fall below $95,000 again, the company risks entering a dangerous downward spiral of declining valuation, increasing skepticism, and further dilution.

What was once considered a premium Bitcoin investment vehicle now trades at a discount, leaving market participants to reconsider the fundamental proposition Strategy offers.

Ad

Strategy Stock: Buy or Sell?! New Strategy Analysis from February 7 delivers the answer:

The latest Strategy figures speak for themselves: Urgent action needed for Strategy investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

Strategy: Buy or sell? Read more here...

Tags: Strategy
Andreas Sommer

Andreas Sommer

About Andreas Sommer Over 40 years of expertise in market analysis, chart technical analysis, and strategic investment advisory. With more than four decades of experience in banking and financial journalism, Andreas Sommer is recognized as one of the leading analysts in the German-speaking market. His deep understanding of market dynamics and technical analysis has helped countless investors navigate complex financial markets.
Areas of Expertise:
  • Technical Chart Analysis
  • Strategic Investment Advisory
  • Market Trend Analysis
  • Financial Journalism
Andreas brings unparalleled insights from his extensive career in banking and financial markets, making him a trusted voice for investors seeking professional guidance.

Related Posts

Orthofix Medical Stock
Earnings

Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio

February 7, 2026
Myers Industries Stock
Analysis

Myers Industries Set to Report Full-Year and Q4 2025 Results

February 7, 2026
OneSpan Stock
Cyber Security

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

February 7, 2026
Next Post
AMD Stock

AMD Sets Sights on Dominance in the AI Chip Arena

Volatus Aerospace Stock

Volatus Aerospace Secures Major Funding for Defense Expansion

Silber Preis Stock

Silver's Rally Stumbles as Fed Comments Trigger Sell-Off

Recommended

Super Micro Computer Stock

Super Micro Stock Surges Amid AI Infrastructure Boom

4 months ago
Adobe Stock

Adobe’s AI Ambitions Face Investor Skepticism

4 months ago
IBM Stock

Strong IBM Earnings Fail to Impress Market as Key Segment Shows Weakness

4 months ago
Inozyme Pharma Inc Stock

Inozyme Pharma Acquisition Finalized: Strategic Focus Shifts to Clinical Development

5 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Myers Industries Set to Report Full-Year and Q4 2025 Results

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

Riley Exploration Permian Bolsters Board with Industry Veteran Amid Shareholder Activity

Great Lakes Dredge & Dock: A Cash Flow Inflection Point Approaches

Investors Await March Report for Boston Omaha’s Strategic Direction

Universal Insurance Maintains Quarterly Payout Amid Sector Headwinds

Trending

Orthofix Medical Stock
Earnings

Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio

by Rodolfo Hanigan
February 7, 2026
0

Investor attention turns to Orthofix Medical as the company bolsters the clinical support for its biologics business...

CrossFirst Bankshares Stock

A New Chapter for First Busey as CrossFirst Merger Finalizes

February 7, 2026
Golden Entertainment Stock

Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

February 7, 2026
Myers Industries Stock

Myers Industries Set to Report Full-Year and Q4 2025 Results

February 7, 2026
OneSpan Stock

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio
  • A New Chapter for First Busey as CrossFirst Merger Finalizes
  • Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com